论文部分内容阅读
本研究用血小板作为免疫原,免疫Balb/C小鼠,并按常规方法进行细胞融合.在筛选时,用血小板、幼稚B细胞(Nalm-6)及EB病毒转化后的人B淋巴母细胞系Raji细胞同时检测杂交瘤细胞上清,仅选与血小板及Nalm-6细胞反应,不与Raji细胞反应的抗体分泌杂交瘤细胞,建立了B9-1、B9-2、B9-3杂交瘤株.根据B9系列抗体与各种血液、造血细胞的反应特点,对通过对肾小球血管内皮及远端曲管上皮反应性及对其相应抗原分子量测定表明,B9系列抗体为CD9类抗体.本系列抗体与某些白血病细胞反应结果表明,与CD10类抗体配伍,可能形成更有效的针对普通型急性淋巴细胞白血病的导向药物.对B9系列抗体在血小板及白血病免疫分型中的研究前景也作了简要讨论.
In this study, Balb / C mice were immunized with platelets and immunized Balb / C mice, and the cells were fused according to the conventional method. At the screening, platelets, naive B cells (Nalm-6) and EB virus transformed human B lymphoblastoid cell line Raji cells simultaneously detected hybridoma cell supernatant, only with platelets and Nalm-6 cells reacted with antibodies that do not react with Raji cells to produce hybridoma cells B9-1, B9-2, B9-3 hybrid strains. According to the reaction characteristics of B9 series antibodies and various blood and hematopoietic cells, the B9 series antibody is a CD9 antibody by reactivity to the glomerular endothelium and distal tubule epithelial cells and their corresponding antigen molecular weight. Antibody and some leukemia cells response results show that, with the CD10 antibody compatibility, may form a more effective for general acute lymphoblastic leukemia-oriented drugs on the B9 series of antibodies in the platelet and leukemia immunophenotyping research also made Brief discussion.